Abstract
Drug discovery remains a complex and time-consuming process, often hindered by inefficiencies and high failure rates. Biomarkers, measurable indicators of biological processes, have emerged as powerful tools to revolutionize this landscape. This article explores the multifaceted role of biomarkers throughout the drug discovery, from target identification and drug development to clinical trials and patient stratification. We highlight how biomarkers enhance our understanding of disease mechanisms, facilitate the selection of promising drug candidates, and enable objective assessment of drug efficacy and safety. Furthermore, the integration of biomarkers with companion diagnostics allows for personalized medicine approaches, tailoring treatment options to individual patient needs. We discuss the various types of biomarkers employed in drug discovery, including genomic, proteomic, and imaging biomarkers, while acknowledging the challenges associated with their validation and regulatory approval. In conclusion, the strategic utilization of biomarkers holds immense potential to streamline drug discovery, accelerate development timelines, and ultimately bring safer and more effective therapies to patients.
Publisher
Innovare Academic Sciences Pvt Ltd